{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-056026","form_type":"8-K/A","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2023-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.405162+00:00","generated_at":"2026-06-09T07:11:44.206619+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pyxis Oncology files Apexigen audited FY22 results; net loss $32M, cash $14.8M","bullets":["Apexigen FY22 net loss of $32.1M, revenue $0; R&D expense $23.0M, G&A $9.7M.","Audited balance sheet at Dec 31, 2022: cash and short-term investments $16.8M, accumulated deficit $176.8M.","Auditors included going-concern doubt; Apexigen had suffered recurring losses and net capital deficiency.","The amendment provides pro forma combined financials as of June 30, 2023 and for FY22, giving effect to the August 23, 2023 acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-056026","json":"https://secwatch.observer/filing/0000950170-23-056026.json","markdown":"https://secwatch.observer/filing/0000950170-23-056026.md","text":"https://secwatch.observer/filing/0000950170-23-056026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023056026/0000950170-23-056026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023056026/pyxs-20230823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T07:11:44.206619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}